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JOURNALS AND DRUG INDUSTRY FUNDED RESEARCH
Evidence on industry influence should be in the core
medical curriculum
Ben Goldacre research fellow
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Smith and colleagues all agree that the drug industry canmislead
doctors and distort medical practice, but they disagree on how
to police the problem.1
One important option has been oddly neglected. The extensive
research evidence documenting industry’s influence on medical
practice should be a core feature of all curriculums for medical
school and membership exams.
Our current model is to give trainees some pointers on basic
study design and critiquing an individual academic manuscript.
This is plainly not enough, given what we now know about the
extent of withheld trial information, misleading trial reports,
manipulation of the academic literature, and the biased
dissemination of evidence through marketing.2
The importance of these problems should not be overlooked.
After initial close supervision and training, doctors go off to
practise medicine independently for several decades. During
this time they are responsible for updating their knowledge,
while medicine changes all around them. Depending on
specialty, doctors who qualified in the 1970s could easily find
themselves almost exclusively using drugs that came on the
market long after they left formal training. Such doctors will
be essentially self taught about these drugs and barraged with
information of variable quality, from an industry with global
revenues of $900bn (£552bn; €666bn), which is incentivised to
keep sales of individual drugs high.
Doctors in this situation should clearly be taught about the
pitfalls in claims made by industry and the evidence on biased
dissemination. This is not a radical suggestion, and it does not
imply that the drug industry—which has createdmany lifesaving
products—is a universally malevolent influence. It is simply a
pragmatic approach to improving evidence based practice, in
the face of influences that seek to distort prescribing decisions.
Competing interests: I am a doctor and a patient. I receive income from
speaking and writing for lay audiences on problems in science and
medicine, including the influence of industry on prescribing.
1 Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by
the drug industry? BMJ 2014;348:g171. (14 January.)
2 Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al.
Information from pharmaceutical companies and the quality, quantity, and cost of
physicians’ prescribing: a systematic review. PLoS Med 2010;7:e1000352.
Cite this as: BMJ 2014;348:g1390
© BMJ Publishing Group Ltd 2014
ben.goldacre@lshtm.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g1390 doi: 10.1136/bmj.g1390 (Published 12 February 2014) Page 1 of 1
Letters
LETTERS
